Coverage
-
February 06, 2018
The Federal Circuit on Tuesday affirmed a district court's finding that Hospira doesn't infringe two blood thinner patents belonging to The Medicines Co., but remanded the question of whether The Medicines Co.'s distribution agreement with another company would render the patents invalid under the so-called on-sale bar.
12 other articles on this case.
View all »